New antibody tested for Tough-to-Treat blood cancer
NCT ID NCT06381141
Summary
This early-stage study is testing the safety and initial effectiveness of an experimental antibody called CLN-619 in adults with multiple myeloma that has returned and stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment can shrink the cancer. About 30 participants will receive the drug to monitor for side effects and early signs of benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Levine Cancer Institute
Winston-Salem, North Carolina, 27157, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering (MSK)
New York, New York, 10065, United States
-
Mt. Sinai
New York, New York, 10029, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.